Researchers led by teams at the University of Oxford reported Thursday in Nature Genetics (opens in new tab) that reactivating the silenced embryonic ζ-globin gene can ameliorate severe forms of α-thalassemia in preclinical models. The open-access paper, published Oct. 1, identifies two repressive cis-regulatory elements in the ζ-globin promoter—binding motifs for BCL11A and LRF (ZBTB7A)—and shows that editing both sites restores ζ-globin expression to levels the authors describe as therapeutically relevant.

Severe α-thalassemia, including transfusion-dependent hemoglobin H (HbH) disease and Hb Bart’s hydrops fetalis syndrome (BHFS), leaves patients without enough α-globin. ζ-globin can form hemoglobin Portland tetramers that can substitute for fetal and adult hemoglobin, but the gene is normally silenced by six to seven weeks of gestation. In a mouse model of Bart’s hydrops, the promoter edits rescued the otherwise prenatally lethal condition until late in development (embryonic day 17.5). In erythroid cells derived from patients with HbH disease and from a BHFS fetus, editing lifted α-like globin levels from below 25% of β-like globin to about 50% after adjusting for editing efficiency, the authors reported.

Corresponding authors Mira T. Kassouf and Douglas R. Higgs and colleagues used CRISPR and base-editing approaches in mouse models, HUDEP-2 cells and CD34+ hematopoietic stem and progenitor cells. They caution that hemoglobin Portland’s physiology in adult life still needs study, that stem-cell editing efficiency in clinical settings may be lower, and that off-target effects and long-term engraftment must be assessed. Four authors are inventors on a pending UK patent application related to the work.

The result is preclinical, and no therapy based on it is available. For now, the only long-term curative treatment for BHFS and transfusion-dependent HbH disease is hematopoietic stem-cell transplantation, which the authors note is limited to the minority of patients with suitable matched donors.